...dialing down the interaction between CD47 on tumors and SIRPA on macrophages, Morphiex lead candidate MBT-001...
...development agreement (CRADA) with NCI and the National Institutes of Health to accelerate development of MBT-001...
...MBT-001 would only block the glycoprotein’s tumor-promoting interaction with CD47, and not its other receptors. MBT-001...

...still are not good inhibitors." The algorithm also may miss druggable targets. The methyllysine-binding protein l(3)mbt-like...

...Cubist issued a "Dear Healthcare Professional" letter warning that an impurity identified as 2-mercaptobenzothiazole (MBT) has...

...12.5 million ($15.4 million). The acquisition includes Munich's EndoTag tumor endothelial cell targeting technology and MBT-0206...
...Munich's VCs paid EUR 4 million in cash to MDG to support further development of MBT-0206...

...12.5 million ($15.4 million). The acquisition includes Munich's EndoTag tumor endothelial cell targeting technology and MBT-0206...
...Munich’s VCs paid EUR 4 million in cash to MDG to support further development of MBT-0206...

...Cancer play Munich Biotech (Neuried, Germany) said it filed for insolvency last week. The company's MBT-0206...
...in Phase II testing to treat metastatic breast cancer and metastatic pancreatic cancer. The company's MBT-0312...

...for metastatic breast cancer and metastatic pancreatic cancer. Munich Biotech AG , Neuried, Germany Product: MBT-0206...

...to the trial if undisclosed milestones are met. Munich Biotech AG , Neuried, Germany Product: MBT-0206...

...to the trial if undisclosed milestones are met. Munich Biotech AG , Neuried, Germany Product: MBT-0206...

...Munich Biotech (Neuried, Germany) began two open label, European Phase II trials of MBT-0206 in about...
...milestones are met. The breast cancer trial will assess tumor response in patients treated with MBT-0206...
...MBT-0206 plus gemcitabine. The company would not comment on how long the trials will take. MBT-0206...